Although panCK+/CD45+ CTC-like cells were detected in the blood of 45 metastatic prostate cancer patients, standardized enrichment protocols and independent validation of their prognostic utility beyond PSA and Gleason score will be essential in future prospective and longitudinal studies. This evidence concerns the gene PTPRC and metastatic prostate carcinoma.